[go: up one dir, main page]

WO1997046520A1 - Derives de 4-nitro-2-phenoxysulfonanilides - Google Patents

Derives de 4-nitro-2-phenoxysulfonanilides Download PDF

Info

Publication number
WO1997046520A1
WO1997046520A1 PCT/JP1997/001867 JP9701867W WO9746520A1 WO 1997046520 A1 WO1997046520 A1 WO 1997046520A1 JP 9701867 W JP9701867 W JP 9701867W WO 9746520 A1 WO9746520 A1 WO 9746520A1
Authority
WO
WIPO (PCT)
Prior art keywords
nitro
phenoxysulfonanilide
inflammatory
analgesic
antipyretic
Prior art date
Application number
PCT/JP1997/001867
Other languages
English (en)
Japanese (ja)
Inventor
Kensei Yoshikawa
Masahiro Hasegawa
Masatoshi Suzuki
Youichi Shimazaki
Mariko Ohtani
Shiuji Saito
Masami Goi
Original Assignee
Taisho Pharmaceutical Co., Ltd.
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Taisho Pharmaceutical Co., Ltd. filed Critical Taisho Pharmaceutical Co., Ltd.
Priority to AU29776/97A priority Critical patent/AU2977697A/en
Publication of WO1997046520A1 publication Critical patent/WO1997046520A1/fr

Links

Classifications

    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07C—ACYCLIC OR CARBOCYCLIC COMPOUNDS
    • C07C311/00—Amides of sulfonic acids, i.e. compounds having singly-bound oxygen atoms of sulfo groups replaced by nitrogen atoms, not being part of nitro or nitroso groups
    • C07C311/50—Compounds containing any of the groups, X being a hetero atom, Y being any atom
    • C07C311/52—Y being a hetero atom
    • C07C311/54—Y being a hetero atom either X or Y, but not both, being nitrogen atoms, e.g. N-sulfonylurea
    • C07C311/55—Y being a hetero atom either X or Y, but not both, being nitrogen atoms, e.g. N-sulfonylurea having sulfur atoms of the sulfonylurea groups bound to acyclic carbon atoms
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07C—ACYCLIC OR CARBOCYCLIC COMPOUNDS
    • C07C311/00—Amides of sulfonic acids, i.e. compounds having singly-bound oxygen atoms of sulfo groups replaced by nitrogen atoms, not being part of nitro or nitroso groups
    • C07C311/50—Compounds containing any of the groups, X being a hetero atom, Y being any atom
    • C07C311/51—Y being a hydrogen or a carbon atom

Definitions

  • the present invention relates to sulfonanilide derivatives having anti-inflammatory, analgesic and antipyretic effects.
  • the present inventors have studied for the purpose of providing a compound having an anti-inflammatory, analgesic, and antipyretic effect, and as a result, have found that a certain sulfonanilide derivative achieves the object, and completed the present invention.
  • the present invention provides
  • R represents a hydrogen atom or an alkyl group having 1 to 5 carbon atoms
  • n represents an integer of 0 to 8
  • Ph represents a phenyl group.
  • It is a 2-phenoxysulfonylanilide derivative.
  • n force is an integer of 1 to 8, it can be produced by the following synthetic route.
  • Ph represents a phenyl group
  • Boc represents a t-butoxycarbonyl group
  • Et represents an ethyl group, and R has the same meaning as described above. Further, when n is an integer of 1 to 8, it can also be produced by the following synthetic route.
  • the compound of the present invention can be administered orally or parenterally in a conventional dosage form.
  • a conventional dosage form are, for example, tablets, granules, powders, powders, capsules, solutions, emulsions, suspensions, injections and the like, all of which can be produced by a usual method using a conventional carrier.
  • the dosage When used as an anti-inflammatory, antipyretic or analgesic in humans, the dosage varies depending on age, body weight, symptoms, route of administration, number of administrations, etc. Usually 5 to 100 Omg per day. Industrial applicability
  • the force lagenin paw edema test was carried out according to the method of Winter et al. [Proc. Soc. Ep. Bio. 1. Med., Vol. 111, p. 544 (1962)].
  • a test subject [compound of the present invention] suspended in a 5% aqueous solution of gum arabic was orally administered to a rat of type 1 Wis rats (6 rats per group) at a dose of 1 lm / 100 g body weight.
  • 1% strength lagenin was subcutaneously administered to the left limb foot 0 at 0.1 im 1.
  • Three hours after the administration of force lagenin the paw volume was measured, and its edema inhibition rate was determined to examine its anti-inflammatory effect.
  • the dose of the sample was set to lmg / kg. Table 1 shows the results. Table 1 Specimen Dose Edema suppression rate

Landscapes

  • Chemical & Material Sciences (AREA)
  • Organic Chemistry (AREA)
  • Organic Low-Molecular-Weight Compounds And Preparation Thereof (AREA)
  • Acyclic And Carbocyclic Compounds In Medicinal Compositions (AREA)

Abstract

Cette invention concerne des dérivés de 4-nitro-2-phénoxysulfonanilides, lesquels correspondent à la formule générale (I) où R représente un atome d'hydrogène ou un groupe alkyle comportant de un à cinq atomes de carbone, tandis que n représente un nombre entier entre 0 et 8. Ces dérivés possèdent d'excellentes activités anti-inflammatoires, analgésiques et antipyrétiques.
PCT/JP1997/001867 1996-06-04 1997-06-02 Derives de 4-nitro-2-phenoxysulfonanilides WO1997046520A1 (fr)

Priority Applications (1)

Application Number Priority Date Filing Date Title
AU29776/97A AU2977697A (en) 1996-06-04 1997-06-02 4-nitro-2-phenoxysulfonanilide derivatives

Applications Claiming Priority (2)

Application Number Priority Date Filing Date Title
JP14055896 1996-06-04
JP8/140558 1996-06-04

Publications (1)

Publication Number Publication Date
WO1997046520A1 true WO1997046520A1 (fr) 1997-12-11

Family

ID=15271482

Family Applications (1)

Application Number Title Priority Date Filing Date
PCT/JP1997/001867 WO1997046520A1 (fr) 1996-06-04 1997-06-02 Derives de 4-nitro-2-phenoxysulfonanilides

Country Status (2)

Country Link
AU (1) AU2977697A (fr)
WO (1) WO1997046520A1 (fr)

Cited By (1)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
EP2780009A4 (fr) * 2011-11-17 2015-05-06 Univ Colorado Regents Procédés et compositions pour une administration améliorée de médicament à l' il et formulations d'administration prolongée

Citations (1)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
JPH06206859A (ja) * 1992-11-20 1994-07-26 Taisho Pharmaceut Co Ltd Ｎ−アシル−５−アミノスルホンアニリド化合物

Patent Citations (1)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
JPH06206859A (ja) * 1992-11-20 1994-07-26 Taisho Pharmaceut Co Ltd Ｎ−アシル−５−アミノスルホンアニリド化合物

Cited By (2)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
EP2780009A4 (fr) * 2011-11-17 2015-05-06 Univ Colorado Regents Procédés et compositions pour une administration améliorée de médicament à l' il et formulations d'administration prolongée
US9562015B2 (en) 2011-11-17 2017-02-07 The Regents Of The University Of Colorado, A Body Methods and compositions for enhanced drug delivery to the eye and extended delivery formulations

Also Published As

Publication number Publication date
AU2977697A (en) 1998-01-05

Similar Documents

Publication Publication Date Title
EP0082088B1 (fr) Nouveaux dérivés d'aminoacides, et leur application thérapeutique
DE69427557T2 (de) Peptide-Analoge mit irreversibler Interleukin-1 Beta-Protease Inhibitoren
EP0526348B1 (fr) Dérivés d'indoline portant une fonction amidique, leur préparation, les compositions pharmaceutiques en contenant
RU2069662C1 (ru) Производные пиразоло [1,5-а] пиридина, или их фармацевтически приемлемые соли и способ их получения
PT101027A (pt) Peptideos, processo para a sua preparacao e sua utilizacao como compostos farmaceuticos
KR100513302B1 (ko) 3-아미노-1,2-벤조이소옥사졸 유도체, 이의 제조방법및 용도
JPH04224554A (ja) リポキシゲナーゼ抑制化合物
FR2963005A1 (fr) Derives d'oxadiazoles et de pyridazines, leur preparation et leur application en therapeutique
JPH07500604A (ja) 高血圧治療用エチルアラニンアミノジオール化合物
FR2758329A1 (fr) Derives d'imidazole-4-butane boronique, leur preparation et leur utilisation en therapeutique
JPH02223548A (ja) リポキシゲナーゼ抑制化合物およびそれを用いたリポキシゲナーゼの抑制方法
WO1997046520A1 (fr) Derives de 4-nitro-2-phenoxysulfonanilides
FI93953C (fi) Menetelmä uusien terapeuttisesti käyttökelpoisten sykloalkyylitiatsolijohdannaisten valmistamiseksi
WO1994018165A1 (fr) Composes de sulfonamide utilises comme agonistes des recepteurs k d'opioides
JP3116256B2 (ja) （チオ）ウレア誘導体
EP0275762B1 (fr) Dérivés de l'indole carboxamide ainsi que leurs sels, procédé et intermédiaires de préparation, application à titre de médicaments de ces dérivés et compositions les renfermant
JPH0430389B2 (fr)
JP2004143053A (ja) β−アミノヒドロキサム酸誘導体およびその用途
US4839358A (en) Alpha-mercaptomethyl-benzene propanamides, pharmaceutical compositions and use
EP0946517A1 (fr) Derives de n-(imidazolylbutyle) benzenesulfonamide ayant une activite antithrombotique
JPH1059927A (ja) ４−ニトロ−２−フェノキシスルホンアニリド誘導体
WO1997047594A1 (fr) Derives de 4-nitrosulfonanilide
HU198446B (en) Process for production of new amids of buten acid and medical compositions containing such active substances
JPH0564946B2 (fr)
JPS6319512B2 (fr)

Legal Events

Date Code Title Description
AK Designated states

Kind code of ref document: A1

Designated state(s): AU CA CN KR US

AL Designated countries for regional patents

Kind code of ref document: A1

Designated state(s): AT BE CH DE DK ES FI FR GB GR IE IT LU MC NL PT SE

DFPE Request for preliminary examination filed prior to expiration of 19th month from priority date (pct application filed before 20040101)
121 Ep: the epo has been informed by wipo that ep was designated in this application
122 Ep: pct application non-entry in european phase
NENP Non-entry into the national phase

Ref country code: CA